Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history

Fig. 2

Moderate/severe exacerbation risk versus BGFa: EOS subgroups by exacerbation history or COPD severity, mITT population. a Treatments compared adjusting for baseline post-bronchodilator percent predicted FEV1, baseline COPD exacerbation history (0, 1, or ≥ 2) in the preceding 12 months, log baseline blood EOS count, region, and ICS use at screening (yes/no) using negative binomial regression; the logarithm of the time at risk of experiencing an exacerbation was used as an offset variable in the model. Abbreviations: BFF: budesonide/formoterol fumarate dihydrate; BGF: budesonide/glycopyrronium/formoterol fumarate dihydrate; CI: confidence interval; COPD: chronic obstructive pulmonary disease; EOS: eosinophil; FEV1: forced expiratory volume in 1 s; GFF: glycopyrronium/formoterol fumarate dihydrate; ICS: inhaled corticosteroid; mITT: modified intention-to-treat; RR: rate ratio

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us